Apparently, over the weekend, Active Biotech completed a deal with the Ipsen Group whereby Ipsen will have responsibilities for the development and marketing of tasquinimod everywhere in the world except North and South America and Japan, where Active Biotech has (so far) retained all development and marketing rights.
As previously reported, Active Biotech recently initiated a randomized, double-blind, multi-center Phase III clinical trial of tasquinimod in asymptomatic or mildly symptomatic, chemotherapy-naive men with metastatic, castration-resistant prostate cancer (mCRPC). According to the joint media release, this deal also implies that Ipsen will be responsible for the development and implementation of a “supportive” clinical trial of tasquinimod in advanced prostate cancer to assist in seeking European approval of the drug. Quite what “supportive” means in that context is unclear. Active Biotech will retain responsibility for the global conduct of the Phase III trial already started.
The Ipsen Group already has experience in the development and marketing of treatments for advanced prostate cancer, since they market sustained-release formulations of the LHRH agonist triptorelin in parts of the world under the brand name Decapeptyl.
Filed under: Drugs in development | Tagged: tasquinimod |
THE "NEW" PROSTATE CANCER INFOLINK 
Are there any clinical trials located in the United States?
Yup … Most of the sites currently recruiting patients for this Phase III trial are in the USA. See the link in the commentary from April 15.